Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity.
Kim DS, Endo A, Fang FG, Huang KC, Bao X, Choi HW, Majumder U, Shen YY, Mathieu S, Zhu X, Sanders K, Noland T, Hao MH, Chen Y, Wang JY, Yasui S, TenDyke K, Wu J, Ingersoll C, Loiacono KA, Hutz JE, Sarwar N. Kim DS, et al. Among authors: sarwar n. ChemMedChem. 2021 Jun 7;16(11):1740-1743. doi: 10.1002/cmdc.202100068. Epub 2021 Feb 25. ChemMedChem. 2021. PMID: 33522135
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Huang KC, Chanda D, McGrath S, Dixit V, Zhang C, Wu J, Tendyke K, Yao H, Hukkanen R, Taylor N, Verbel D, Kim DS, Endo A, Noland TA, Chen Y, Matijevic M, Wang J, Hutz J, Sarwar N, Fang FG, Bao X. Huang KC, et al. Among authors: sarwar n. Mol Cancer Ther. 2022 Jun 1;21(6):914-924. doi: 10.1158/1535-7163.MCT-21-0780. Mol Cancer Ther. 2022. PMID: 35313332
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Huang KC, Chandra D, McGrath S, Dixit V, Zhang C, Wu J, Tendyke K, Yao H, Hukkanen R, Taylor N, Verbel D, Kim DS, Endo A, Noland TA, Chen Y, Matijevic M, Wang J, Hutz J, Sarwar N, Fang FG, Bao X. Huang KC, et al. Among authors: sarwar n. Mol Cancer Ther. 2023 Apr 3;22(4):551. doi: 10.1158/1535-7163.MCT-23-0121. Mol Cancer Ther. 2023. PMID: 37009707 No abstract available.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma.
Culliford R, Lawrence SED, Mills C, Tippu Z, Chubb D, Cornish AJ, Browning L, Kinnersley B, Bentham R, Sud A, Pallikonda H; Renal Cancer Genomics England Consortium; Frangou A, Gruber AJ, Litchfield K, Wedge D, Larkin J, Turajlic S, Houlston RS. Culliford R, et al. Nat Commun. 2024 Jul 15;15(1):5935. doi: 10.1038/s41467-024-49692-1. Nat Commun. 2024. PMID: 39009593 Free PMC article.
Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study.
Connor MJ, Genie M, Dudderidge T, Wu H, Sukumar J, Beresford M, Bianchini D, Goh C, Horan G, Innominato P, Khoo V, Klimowska-Nassar N, Madaan S, Mangar S, McCracken S, Ostler P, Paisey S, Robinson A, Rai B, Sarwar N, Srihari N, Jayaprakash KT, Varughese M, Winkler M, Ahmed HU, Watson V; IP5-MATTER Trial Investigators. Connor MJ, et al. Among authors: sarwar n. Eur Urol Oncol. 2024 Jul 6:S2588-9311(24)00158-5. doi: 10.1016/j.euo.2024.06.010. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38972831 Free article.
168 results